Cancer in Low- and Middle-Income Countries: An Economic Overview

Abstract

No AccessNov 2015Cancer in Low- and Middle-Income Countries: An Economic OverviewAuthors/Editors: Susan Horton, Cindy L. GauvreauSusan HortonSearch for more papers by this author, Cindy L. GauvreauSearch for more papers by this authorhttps://doi.org/10.1596/978-1-4648-0349-9_ch16View ChaptersAboutFull TextPDF (0.2 MB) ToolsAdd to favoritesDownload CitationsTrack Citations ShareFacebookTwitterLinked In Abstract: Reviews the economics in health care system design and implementation by looking at patterns of cancer care resources across countries for surgery, radiotherapy, medications, laboratories and pathology, cancer registries, skilled medical personnel, health insurance and international partnerships. Cost-effectiveness of interventions is discussed for six types of cancers: cervical, breast, childhood, colon, liver, and oral. The dearth of literature on cost-effectiveness in low- and middle-income countries (LMICs) points out the need for more studies, especially for surgery which is considered the cornerstone of cancer treatments. Future economics work on cancer is to cost out the ingredients required for the priority interventions, such that costs of resource-appropriate care can be estimated in individual countries. ReferencesAballéa, S, A Boler, A Craig, and H Wasan. 2007. “An economic evaluation of oxaliplatin for the Adjuvant Treatment of Colon Cancer in the United Kingdom.” European Journal of Cancer 43 (11): 1687–93. CrossrefGoogle ScholarArmstrong, K, T M Chen, D Albert, T C Randall, and J S Schwartz. 2001. “Cost-Effectiveness of Raloxifene and Hormone Replacement Therapy in Postmenopausal Women: Impact of Breast Cancer Risk.” Obstetrics Gynecology 98 (6): 996–1003. CrossrefGoogle ScholarAvksentyeva, M 2010. “Colorectal Cancer in Russia.” European Journal of Health Economics 1: S91–S98. CrossrefGoogle ScholarBeutels, P 2001. “Economic Evaluations of Hepatitis B Immunization: A Global Review of Recent Studies (1994–2000).” Health Economics 10 751–74. CrossrefGoogle ScholarBhakta, N, A L C Martiniuk, S Gupta, and S C Howard. 2013. “The Cost-Effectiveness of Treating Paediatric Cancer in Low-Income and Middle-Income Countries: A Case-Study Approach Using Acute Lymphocytic Leukaemia in Brazil and Burkitt Lymphoma in Malawi.” Archives of Disease in Children 98 (2): 155–60. CrossrefGoogle ScholarCameron, D A, D R Camidge, J Oyee, and M Hirsch. 2008. “Economic Evaluation of Fulvestrant as an Extra Step in the Treatment Sequence for ER-Positive Advanced Breast Cancer.” British Journal of Cancer 99 (12): 1984–90. CrossrefGoogle ScholarCampos, N G, J J Kim, P E Castle, J Ortendahl, and M O’Shea others. 2012. “Health and Economic Impact of HPV 16/18 Vaccination and Cervical Cancer Screening in Eastern Africa.” International Journal of Cancer 130 (11): 2672–84. CrossrefGoogle ScholarCommission on Macroeconomics and Health. 2001. WHO. Macroeconomics and Health: Investing in Health for Economic Development. Geneva: World Health Organization. http://whqlibdoc.who.int/publications/2001/924154550x.pdf. Google ScholarCurado, M P, B Edwards, H R Shim, H Storm, and J Ferlay others, eds. 2007. Cancer Incidence in Five Continents, vol. IX. Scientific Publications 160. Lyon: International Agency for Research on Cancer. Google Scholarde Lima Lopes, G 2011. “Societal Costs and Benefits of Treatment with Trastuzumab in Patients with Early HER2neu-Overexpressing Breast Cancer in Singapore.” BMC Cancer 11 178–85. CrossrefGoogle Scholarde Verteuil, R M, R A Hernández, and L Vale. 2007. “Economic Evaluation of Laparoscopic Surgery for Colorectal Cancer.” International Journal of Technology Assessment in Health Care 23 (4): 464–72. CrossrefGoogle ScholarDedhia, R C, K J Smith, J T Johnson, and M Roberts. 2011. “The Cost-Effectiveness of Community-Based Screening for Oral Cancer in High-Risk Males in the United States: A Markov Decision Analysis Approach.” Laryngoscope 121 (5): 952–60. CrossrefGoogle ScholarDelea, T E, J Karnon, O Sofrygin, S K Thomas, N L Papo, and V Barghout. 2007. “Cost-effectiveness of Letrozole versus Tamoxifen as Initial Adjuvant Therapy in Hormone-receptor-positive Postmenopausal Women with Early-stage Breast Cancer.” Clinical Breast Cancer 7 (8): 608–18. CrossrefGoogle ScholarDesch, C E, B E Hillner, T J Smith, and S M Retchin. 1993. “Should the Elderly Receive Chemotherapy for Node-Negative Breast Cancer? A Cost-Effectiveness Analysis Examining Total and Active Life-Expectancy Outcomes.” Journal of Clinical Oncology 11 (4): 777–82. Google ScholarDranitsaris, G, S Verma, and M Trudeau. 2003. “Cost Utility Analysis of First-line Hormonal Therapy in Advanced Breast Cancer: Comparison of Two Aromatase Inhibitors to Tamoxifen.” American Journal of Clinical Oncology 26(3):289–96. Google ScholarDrummond, M F, M J Schulpher, G W Torrance, D J O’Brien, and G L Stoddart. 2005. Methods for the Economic Evaluation of Health Care Programmes. 3rd edition. New York: Oxford University Press. Google ScholarEssers, B A, S C Seferina, V C Tjan-Heijnen, J L Severens, and A Novák others. 2010. “Transferability of Model-Based Economic Evaluations: The Case of Trastuzumab for the Adjuvant Treatment of HER2-Positive Early Breast Cancer in the Netherlands.” Value in Health 13 (4): 375–80. CrossrefGoogle ScholarFonseca, M, G T B Araújo, and E D Saad. 2009. “Cost-Effectiveness of Anastrozole, in Comparison with Tamoxifen, in the Adjuvant Treatment of Early Breast Cancer in Brazil.” Revista Da Associação Medica Brasileira 55 410–15. CrossrefGoogle ScholarFunk, L M, T G Weiser, W R Berry, S R Lipsitz, and A F Merry others. 2010. “Global Operating Theatre Distribution and Pulse Oximetry Supply: An Estimation from Reported Data.” Lancet 376 (9746): 1055–61. CrossrefGoogle ScholarGil, J M, C Rubio-Terres, C A Del, P Gonzalez, and F Canorea. 2006. “Pharmacoeconomic Analysis of Adjuvant Therapy with Exemestane, Anastrozole, Letrozole or Tamoxifen in Postmenopausal Women with Operable and Estrogen Receptor-Positive Breast Cancer” Clinical Transl Oncology 8 (5): 339–48. CrossrefGoogle ScholarGinsberg, G M, J A Lauer, S Zelle, S Baetan, and R Baltussen. 2012. “Cost Effectiveness of Strategies to Combat Breast, Cervical, and Colorectal Cancer in sub-Saharan Africa and South East Asia: Mathematical Modelling Study.” British Medical Journal 344: eb14. doi:10.1136/bmj.e614. CrossrefGoogle ScholarGoldie, S J, L Gaffikin, J D Goldhaber-Fiebert, A Gordillo-Tobar, and C Levin others. 2005. “Cost-Effectiveness of Cervical-Cancer Screening in Five Developing Countries.” New England Journal of Medicine 353 2158–68. CrossrefGoogle ScholarGreenberg, D, C Earle, C H Fang, A Eldar-Lissai, and P J Neumann. 2010. “When Is Cancer Care Cost-Effective? A Systematic Overview of Cost-Utility Analyses in Oncology.” Journal of the National Cancer Institute 102 (2): 82–88. CrossrefGoogle ScholarHayes, J L and P Hansen. 2007. “Is Laparoscopic Colectomy for Cancer Cost-Effective Relative to Open Colectomy?” Australia and New Zealand Journal of Surgery 77 (9): 782–86. CrossrefGoogle ScholarHedden, L, S O’Reilly, C Lohrisch, S Chia, and C Speers others. 2012. “Assessing the Real-World Cost-Effectiveness of Adjuvant Trastuzumab in HER-2/neu Positive Breast Cancer.” Oncologist 17 (2): 164–71. CrossrefGoogle ScholarHillner, B E and T J Smith. 1991. “Efficacy and Cost Effectiveness of Adjuvant Chemotherapy in Women with Node-Negative Breast Cancer. A Decision-Analysis Model.” New England Journal of Medicine 324 (3): 160–68. CrossrefGoogle ScholarHillner, B E and T J Smith. 1993. “Assessing the Cost Effectiveness of Adjuvant Therapies in Early Breast Cancer Using a Decision Analysis Model.” Breast Cancer Research and Treatment 25 (2): 97–105. CrossrefGoogle ScholarIAEA (International Atomic Energy Authority). 2013. “Radiotherapy Availability.” Programme of Action for Cancer Therapy (PACT), Programme Office. http://cancer.iaea.org/agart.asp. Google ScholarIshiguro, H, M Kondo, S L Hoshi, M Takada, and S Nakamura others. 2010. “Economic Evaluation of Intensive Chemotherapy with Prophylactic Granulocyte Colony-Stimulating Factor for Patients with High-Risk Early Breast Cancer in Japan.” Clinical Therapeutics 32 (2): 11–26. CrossrefGoogle ScholarKarnon, J, R Delea, S R Johnston, R Smith, J Brandman, and J Sung others 2003. “Cost-effectiveness of Extended Adjuvant Letrozole in Postmenopausal Women after Adjuvant Tamoxifen Therapy: the UK Perspective. Pharmacoeconomics 24 (3): 237–50. CrossrefGoogle ScholarKim, J J, K E Kobus, M Diaz, V Van Minh, and S J Goldie. 2008. “Exploring the Cost-Effectiveness of HPV Vaccination in Vietnam: Insights for Evidence-Based Cervical Cancer Prevention Policy.” Vaccine 26 4015–24. CrossrefGoogle ScholarKhlangwiset, P and F Wu. 2010. “Costs and Efficacy of Public Health Interventions to Reduce Aflatoxin-induced Human Disease.” Food Additives and Contaminants Part A Chemical Analysis, Control of Exposure and Risk Assessment 27(7): 998–1014. Google ScholarKnaul, F M, E E González-Pier, O Gómez-Dantés, D García-Junco, and H Arreola-Ornelas others. 2012. “The Quest for Universal Health Coverage: Achieving Social Protection for All in Mexico.” Lancet 350 1259–79. CrossrefGoogle ScholarLee, S Y, S H Jeong, Y N Kim, J Kim, and D R Kang others. 2009. “Cost-Effective Mammography Screening in Korea: High Incidence of Breast Cancer in Young Women.” Cancer Science 100: 1105–1111. CrossrefGoogle ScholarLevin, C E, J Sellors, J -F Shi, L Ma, Y -L Qiao, J Ortendahl, M K H O’Shea, and S J Goldie. 2010. “Cost-effectiveness Analysis of Cervical Cancer Prevention based on a Rapid Human Papillomavirus Screening Test in a High-Risk Region of China.” International Journal of Cancer 127 1404–11. CrossrefGoogle ScholarLiberato, N L, M Marchetti, and G Barosi. 2007. “Cost-Effectiveness of Adjuvant Trastuzumab in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.” Journal of Clinical Oncology. 25(6):625–33. CrossrefGoogle ScholarLuo, X Q, Z Y Ke, L B Huang, X Q Guan, and Y C Zhang others. 2009. “Improved Outcome for Chinese Children with Acute Promyelocytic Leukemia: A Comparison of Two Protocols.” Pediatric Blood and Cancer 53 325–28. CrossrefGoogle ScholarMalin, J L, E Keeler, C Wang, and R Brook. 2002. “Using Cost-Effectiveness Analysis to Define a Breast Cancer Benefits Package for the Uninsured.” Breast Cancer Research and Treatment 74 (2): 143–53. CrossrefGoogle ScholarMontero, A J, K Avancha, S Glück, and G Lopes. 2012. “A Cost-Benefit Analysis of Bevacizumab in Combination with Paclitaxel in the First-Line Treatment of Patients with Metastatic Breast Cancer.” Breast Cancer Research and Treatment 132 (2): 747–51. CrossrefGoogle ScholarNaeim, A and E B Keeler. 2005. “Is Adjuvant Therapy for Older Patients with Node (-) Early Breast Cancer Cost-Effective?” Critical Reviews in Oncology/Hematology 53 (1): 81–89. CrossrefGoogle ScholarNguyen, L H, W Laohasiriwong, J F Stewart, P Wright, Y T B Nguyen, and P C Coyte. 2013. “Cost-effectiveness Analysis of a Screening Program for Breast Cancer in Vietnam.” Value in Health Regional Issues 2 21–28. CrossrefGoogle ScholarNorum, J, V Angelsen, E Wist, and J A Olsen. 1996. “Treatment Costs in Hodgkin’s Disease: A Cost-Utility Analysis.” European Journal of Cancer 32A (9):1510–17. CrossrefGoogle ScholarNorum, J, J A Olsen, and E A Wist. 1997. “Lumpectomy or mastectomy? Is breast conserving surgery too expensive?” Breast Cancer Research and Treatment 45 (1): 7–14. CrossrefGoogle ScholarOkonkwo, Q L, G Draisma, A der Kinderen, M L Brown, and H J de Koning. 2008. “Breast Cancer Screening Policies in Developing Countries: A Cost-Effectiveness Analysis for India.” Journal of the National Cancer Institute 100 (18): 1290–1300. CrossrefGoogle ScholarOzawa, S, A Mirelman, M L Stacka, D G Walker, and O S Levine. 2012. “Cost-Effectiveness and Economic Benefits of Vaccines in Low- and Middle-Income Countries: A Systematic Review.” Vaccine 31 108–96. CrossrefGoogle ScholarPark, S M, Y H Yun, and S Kwon. 2005. “Feasible Economic Strategies to Improve Screening Compliance for Colorectal Cancer in Korea.” World Journal of Gastroenterology 11 1587–93. CrossrefGoogle ScholarPignone, M, L Russell, and J Wagner eds. 2005. Economic Models of Colorectal Cancer Screening in Average-Risk Adults. Washington, DC: National Academies Press. Google ScholarPraditsitthikorn, N, Y Teerawattananon, S Tantivess, S Limwattananon, and A Riewpaiboon others. 2011. “Economic Evaluation of Policy Options for Prevention and Control of Cervical Cancer in Thailand.” Pharmacoeconomics 29 (9): 781–806. CrossrefGoogle ScholarRamsey, S D, Z Liu, R Boer, S D Sullivan, and J Malin others. 2009. “Cost-Effectiveness of Primary versus Secondary Prophylaxis with Pegfilgrastim in Women with Early-Stage Breast Cancer Receiving Chemotherapy.” Value in Health 12 (2): 217–25. CrossrefGoogle ScholarReid, S 2012. “Estimating the Burden of Disease from Unsafe Injections in India: A Cost-Benefit Assessment of the Auto-Disable Syringe in a Country with Low Blood-Borne Virus Prevalence.” Indian Journal of Community Medicine 37 (2): 89–94. doi:10.4103/0970-0218.96093. CrossrefGoogle ScholarRodgers, M, M Soares, D Epstein, H Yang, and D Fox others. 2011. “Bevacizumab in Combination with a Taxane for the First-Line Treatment of HER2-Negative Metastatic Breast Cancer.” Health Technology Assessment 1 1–12. CrossrefGoogle ScholarSalomon, J A, N Carvalho, C Gutiérrez-Delgado, R Orozco, and A Mancuso others. 2012. “Intervention Strategies to Reduce the Burden of Non-Communicable Diseases in Mexico: Cost Effectiveness Analysis.” British Medical Journal 344: e355. Google ScholarSloan, F A and H Gelband eds. 2007. Opportunities for Cancer Control in Low- and Middle-Income Countries. Washington, DC: National Academies Press. Google ScholarSmith, R D, J Hall, H Gurney, and P R Harnett. 1993. “A Cost-Utility Approach to the Use of 5-Fluorouracil and Levamisole as Adjuvant Chemotherapy for Dukes’ C Colonic Carcinoma.” Medical Journal of Australia 158 (5): 319–22. Google ScholarSpeight, P M, S Palmer, D R Moles, M C Downer, and D H Smith others. 2006. “The Cost-Effectiveness of Screening for Oral Cancer in Primary Care.” Health Technology Assessment 10 (14): 1–144. CrossrefGoogle ScholarStarling, N, D Tilden, J White, and D Cunningham. 2007. “Cost-Effectiveness Analysis of Cetuximab/Irinotecan vs Active/Best Supportive Care for the Treatment of Metastatic Colorectal Cancer Patients Who Have Failed Previous Chemotherapy Treatment.” British Journal of Cancer 96 (2): 206–12. CrossrefGoogle ScholarSubramanian, S, R Sankaranarayanan, B Bapat, T Somanathan, and G Thomas others. 2009. “Cost-Effectiveness of Oral Cancer Screening: Results from a Cluster Randomized Controlled Trial in India.” Bulletin of the World Health Organization 87 (3): 200–06. CrossrefGoogle ScholarTappenden, P, R Jones, S Paisley, and C Carroll. 2007. “The Cost-Effectiveness of Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer in England and Wales.” European Journal of Cancer 17 (2487): 2494. Google ScholarTsoi, K K F, S S M Ng, M C M Leung, and J J Y Sung. 2008. “Cost-Effectiveness Analysis on Screening for Colorectal Neoplasm and Management of Colorectal Cancer in Asia.” Alimentary Pharmacology and Therapeutics 28 (3): 353–63. CrossrefGoogle Scholarvan den Brink, M, W B van den Hout, A M Stiggelbout, E Klein Kranenbarg, and C A Marijnen others. 2004. “Cost-Utility Analysis of Preoperative Radiotherapy in Patients with Rectal Cancer Undergoing Total Mesorectal Excision: A Study of the Dutch Colorectal Cancer Group.” Journal of Clinical Oncology 22 (2): 244–53. CrossrefGoogle Scholarvan der Meij, E H, P D Bezemer, and I van der Waal. 2002. “Cost-Effectiveness of Screening for the Possible Development of Cancer in Patients with Oral Lichen Planus.” Community Dentistry and Oral Epidemiology 30 (5): 342–52. CrossrefGoogle Scholarvan Litsenburg, R R, C A Uyl-de Groot, H Raat, G J Kaspers, and R J Gemke. 2011. “Cost-Effectiveness of Treatment of Childhood Acute Lymphoblastic Leukemia with Chemotherapy Only: The Influence of New Medication and Diagnostic Technology.” Pediatric Blood and Cancer 57 (6): 1005–10. CrossrefGoogle Scholarvan Vlaenderen, I, J L Canon, V Cocquyt, G Jerusalem, and J P Machiels others. 2009. “Trastuzumab Treatment of Early Stage Breast Cancer Is Cost-Effective from the Perspective of the Belgian Health Care Authorities.” Acta Clinica Belgica 64 (2): 100–12. CrossrefGoogle ScholarVos, T, R Carter, J Barendregt, C Mihalopoulos, L Veerman, A Magnus, L Cobiac, M Bertram, and A Wallace. 2010. Assessing Cost-Effectiveness in Prevention: Final Report. University of Queensland, Brisbane and Deakin University, Melbourne. Google ScholarWHO (World Health Organization). 2012. Assessing National Capacity for the Prevention and Control of Noncommunicable Diseases: Report of the 2010 Global Survey. Geneva: WHO. Google ScholarWong, I O L, K M Kuntz, B J Cowling, C L K Lam, and G M Leung. 2007. “Cost Effectiveness of Mammography Screening for Chinese Women.” Cancer 110 (885): 895. Google ScholarWong, S S, A P K Leong, and T Z Leong. 2004. “Cost-Effectiveness Analysis of Colorectal Cancer Screening Strategies in Singapore: A Dynamic Decision Analytic Approach.” Studies in Health Technology Information 107 (Pt 1):104–10. Google ScholarWorld Bank. 2013. World Databank. World Bank, Washington, DC. http://databank.worldbank.org/data/home.aspx. Google ScholarWu, G H -M, Y -M Wang, A M -F Yen, J -M Wong, and H -C Lai others. 2006. “Cost-Effectiveness Analysis of Colorectal Cancer Screening with Stool DNA Testing in Intermediate-Incidence Countries.” BMC Cancer 6 136–48. CrossrefGoogle ScholarYang, J J, S K Park, L Y Cho, W Han, and B Park others. 2010. “Cost-Effectiveness Analysis of 5 Years of Postoperative Adjuvant Tamoxifen Therapy for Korean Women with Breast Cancer: Retrospective Cohort Study of the Korean Breast Cancer Society Database.” Clinical Therapeutics 32 1122–38. CrossrefGoogle ScholarZelle, S G, K M Nyarko, W K Bosu, M Aikins, and L M Niëns others. 2012. “Costs, Effects and Cost-Effectiveness of Breast Cancer Control in Ghana.” Tropical Medicine and International Health 17 1031–43. CrossrefGoogle Scholar Previous chapterNext chapter FiguresreferencesRecommendeddetailsCited bySurvival pattern of colorectal cancer in Sub-Saharan Africa: A systematic review and meta-analysisCancer Epidemiology, Vol.81Secondary Prevention of Cervical Cancer: ASCO Resource–Stratified Guideline UpdateJCO Global Oncology, Vol.18, No.8Priorities for cancer research in low- and middle-income countries: a global perspectiveNature Medicine, Vol.28, No.419 April 2022Innate and Adaptive Immunopathogeneses in Viral Hepatitis; Crucial Determinants of Hepatocellular CarcinomaCancers, Vol.14, No.528 February 2022A pilot study to explore societal, patient, and public authority perception on ‘Value-Added Tax’ system for healthcare financing in Zimbabwe: A case for cancer treatmentJournal of Oncology Pharmacy Practice, Vol.1327 January 2022Modeling the Cost-Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer in South African Public HospitalsJCO Global Oncology, Vol.37, No.7Risk Factors Associated with Breast Cancer among Women in Addis Ababa, Ethiopia: Unmatched Case–Control StudyInternational Journal of Women's Health, Vol.Volume 131 January 2021Limited Access to Care for Persons with Breast Cancer in Africa: A Systematic ReviewEuropean Journal of Oncology NursingTreatment of Patients With Late-Stage Colorectal Cancer: ASCO Resource-Stratified GuidelineJCO Global Oncology, Vol.44, No.6Radiation Therapy in Gabon: Multi-Institutional Collaboration as a Paradigm for Growth in the African Radiation Oncology SectorInternational Journal of Radiation Oncology*Biology*Physics, Vol.106, No.4Health-care investments for the urban populations, Bangladesh and IndiaBulletin of the World Health Organization, Vol.98, No.121 October 2019Early Detection for Colorectal Cancer: ASCO Resource-Stratified GuidelineJournal of Global Oncology, Vol.60, No.5Late Presentation of Breast Cancer in Lower- and Middle-Income CountriesCurrent Breast Cancer Reports, Vol.11, No.320 June 2019Early Detection for Colorectal Cancer: ASCO Resource-Stratified Guideline SummaryJournal of Oncology Practice, Vol.15, No.5Sixth Year of the Symposium on Global Cancer Research: Enhancing Communication and Collaboration to Support Improved Cancer Prevention and ControlJournal of Global Oncology, Vol.4, No.Supplement 1Cost-Effectiveness Analysis in Disease Control Priorities, Third Edition3 January 2018Secondary Prevention of Cervical Cancer: ASCO Resource-Stratified Clinical Practice GuidelineJournal of Global Oncology, Vol.3, No.5Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified GuidelineJournal of Global Oncology, Vol.3, No.5Primary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Guideline SummaryJournal of Oncology Practice, Vol.13, No.7Secondary Prevention of Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline SummaryJournal of Oncology Practice, Vol.13, No.2Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice GuidelineJournal of Global Oncology, Vol.2, No.5Management and Care of Women With Invasive Cervical Cancer: ASCO Resource-Stratified Clinical Practice GuidelineJournal of Clinical Oncology, Vol.34, No.27Disparities in access to preventive health care services among insured children in a cross sectional studyMedicine, Vol.95, No.28Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline SummaryJournal of Oncology Practice, Vol.12, No.7Summary9 November 2015 View Published: November 2015ISBN: 978-1-4648-0349-9e-ISBN: 978-1-4648-0369-7 Copyright & Permissions Related TopicsHealth Nutrition and Population KeywordsCASE STUDYPREVENTION AND DIAGNOSISCANCERHEALTH FINANCECOST-EFFECTIVENESSLOW-INCOME COUNTRIESMIDDLE-INCOME COUNTRIESMEDICAL EQUIPMENT AND SUPPLIESQUALITY OF HEALTH CARECHEMOTHERAPYRADIATION THERAPYBREAST CANCERCERVICAL CANCERCOLON CANCERORAL CANCERCANCER SCREENINGCHILD HEALTHRESEARCH NEEDS PDF downloadLoading ...